DK1083924T3 - Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance - Google Patents

Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance

Info

Publication number: DK1083924T3
Authority: DK; Denmark
Prior art keywords: glp; glucagon; individuals; peptide; glucose
Prior art date: 1998-06-12

Application number

DK99921778T

Other languages

Danish (da)

English (en)

Inventor

Maria Byrne

Burkhard Goke

Thomas R Coolidge

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-05-07

Publication date

2004-11-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22215287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1083924(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-05-07 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2004-11-22 Application granted granted Critical

2004-11-22 Publication of DK1083924T3 publication Critical patent/DK1083924T3/da

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
208000002705 Glucose Intolerance Diseases 0.000 title 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title 1
230000036755 cellular response Effects 0.000 title 1
239000008103 glucose Substances 0.000 title 1
201000009104 prediabetes syndrome Diseases 0.000 title 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK99921778T 1998-06-12 1999-05-07 Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance DK1083924T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8904498P	1998-06-12	1998-06-12
EP99921778A EP1083924B1 (fr)	1998-06-12	1999-05-07	Peptide 1 analogue au glucagon (glp-1), permettant d'ameliorer la reponse des cellules beta au glucose chez des sujets ayant une deficience de la tolerance au glucose

Publications (1)

Publication Number	Publication Date
DK1083924T3 true DK1083924T3 (da)	2004-11-22

Family

ID=22215287

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99921778T DK1083924T3 (da)	1998-06-12	1999-05-07	Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance

Country Status (30)

Country	Link
US (1)	US7265087B1 (fr)
EP (2)	EP1083924B1 (fr)
JP (1)	JP2002517469A (fr)
KR (1)	KR20010052800A (fr)
CN (1)	CN1209166C (fr)
AP (1)	AP2001002027A0 (fr)
AT (1)	ATE270897T1 (fr)
AU (2)	AU758825B2 (fr)
BG (1)	BG64975B1 (fr)
BR (1)	BR9911112A (fr)
CA (1)	CA2334872C (fr)
CZ (1)	CZ294848B6 (fr)
DE (1)	DE69918691T2 (fr)
DK (1)	DK1083924T3 (fr)
EA (1)	EA004538B1 (fr)
ES (1)	ES2224659T3 (fr)
GE (1)	GEP20033015B (fr)
HU (1)	HUP0102193A2 (fr)
ID (1)	ID28617A (fr)
IL (2)	IL140223A0 (fr)
MX (1)	MXPA00012286A (fr)
NO (1)	NO20006336L (fr)
NZ (2)	NZ508823A (fr)
OA (1)	OA11694A (fr)
PL (1)	PL195662B1 (fr)
PT (1)	PT1083924E (fr)
SK (1)	SK19042000A3 (fr)
TR (1)	TR200100079T2 (fr)
UA (1)	UA69412C2 (fr)
WO (1)	WO1999064061A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US20020025306A1 (en) *	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP2206720A1 (fr)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
CA2430934C (fr)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	Procede de production de preparations d'une substance bioactive a liberation prolongee a l'aide de gaz haute pression
EP2261250B1 (fr)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	Protéines de fusion d'albumine et GCSF
US6923175B2 (en)	2002-03-20	2005-08-02	Mannkind Corporation	Inhalation apparatus
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (fr)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
US8921311B2 (en) *	2003-08-01	2014-12-30	Mannkind Corporation	Method for treating hyperglycemia
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
KR20130066695A (ko)	2004-08-23	2013-06-20	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2006083761A2 (fr)	2005-02-03	2006-08-10	Alza Corporation	Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
EP1886692A4 (fr) *	2005-05-27	2009-09-30	Asubio Pharma Co Ltd	Agent d amelioration de la resistance a l insuline
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (fr)	2006-02-22	2017-10-25	MannKind Corporation	Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif
ES2495741T3 (es)	2006-04-20	2014-09-17	Amgen, Inc	Compuestos de GLP-1
MX2008014870A (es)	2006-05-30	2009-02-12	Intarcia Therapeutics Inc	Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (fr)	2006-08-09	2012-11-14	Intarcia Therapeutics, Inc.	Systemes d'administration osmotiques et ensembles pistons
RU2413528C2 (ru)	2007-01-18	2011-03-10	Открытое Акционерное Общество "Валента Фармацевтика"	Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
HRP20130259T1 (hr)	2007-04-23	2013-04-30	Intarcia Therapeutics, Inc.	Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
KR20100057640A (ko) *	2007-09-11	2010-05-31	몬도바이오테크 래보래토리즈 아게	치료제로서의 인슐린 ｃ-펩티드 단독 또는 ｇｌｐ-1과의 배합물의 용도
US20100204113A1 (en) *	2007-09-11	2010-08-12	Dorian Bevec	Use of stresscopin-related peptide as a therapeutic agent
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CN101827626B (zh)	2008-06-13	2015-03-18	曼金德公司	干粉吸入器和用于药物输送的系统
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
US20120058105A1 (en) *	2008-06-27	2012-03-08	Martin Kean Chong Ng	Method of treatment of vascular complications
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
SMT201700583T1 (it)	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
CN102985125A (zh)	2010-06-21	2013-03-20	曼金德公司	干粉药物输送系统和方法
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG194034A1 (en)	2011-04-01	2013-11-29	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
MX2014004983A (es)	2011-10-24	2014-09-22	Mannkid Corp	Metodos y composiciones para tratar dolor.
EP2873422A4 (fr)	2012-07-10	2015-12-30	Takeda Pharmaceutical	Préparation pharmaceutique pour l'injection
KR102264177B1 (ko)	2012-07-12	2021-06-11	맨카인드 코포레이션	건조 분말 약물 전달 시스템 및 방법
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (fr)	2013-08-05	2020-10-07	MannKind Corporation	Appareil d'insufflation
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
EP3080152A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
WO2015086728A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru)	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
CN104267194B (zh) *	2014-09-23	2016-01-13	上海市东方医院	人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
RU2760007C2 (ru)	2016-05-16	2021-11-22	Интарсия Терапьютикс, Инк.	Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN111171134B (zh) *	2018-11-12	2023-08-15	天津药物研究院有限公司	胰高血糖素衍生肽及其用途
CN113430154A (zh) *	2021-05-21	2021-09-24	深圳市前海金卓生物技术有限公司	分泌glp-1的蛋白表达系统及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59712555D1 (de)	1996-06-05	2006-04-06	Roche Diagnostics Gmbh	Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6344180B1 (en) *	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes

1999
- 1999-05-07 SK SK1904-2000A patent/SK19042000A3/sk unknown
- 1999-05-07 WO PCT/US1999/010040 patent/WO1999064061A1/fr not_active Ceased
- 1999-05-07 DK DK99921778T patent/DK1083924T3/da active
- 1999-05-07 EP EP99921778A patent/EP1083924B1/fr not_active Revoked
- 1999-05-07 DE DE69918691T patent/DE69918691T2/de not_active Revoked
- 1999-05-07 AT AT99921778T patent/ATE270897T1/de not_active IP Right Cessation
- 1999-05-07 CN CNB998091812A patent/CN1209166C/zh not_active Expired - Fee Related
- 1999-05-07 JP JP2000553129A patent/JP2002517469A/ja active Pending
- 1999-05-07 US US09/719,410 patent/US7265087B1/en not_active Expired - Fee Related
- 1999-05-07 TR TR2001/00079T patent/TR200100079T2/xx unknown
- 1999-05-07 AP APAP/P/2001/002027A patent/AP2001002027A0/en unknown
- 1999-05-07 PT PT99921778T patent/PT1083924E/pt unknown
- 1999-05-07 ID IDW20010100A patent/ID28617A/id unknown
- 1999-05-07 IL IL14022399A patent/IL140223A0/xx unknown
- 1999-05-07 KR KR1020007014110A patent/KR20010052800A/ko not_active Ceased
- 1999-05-07 OA OA1200000341A patent/OA11694A/en unknown
- 1999-05-07 GE GEAP19995661A patent/GEP20033015B/en unknown
- 1999-05-07 CZ CZ20004614A patent/CZ294848B6/cs not_active IP Right Cessation
- 1999-05-07 CA CA2334872A patent/CA2334872C/fr not_active Expired - Fee Related
- 1999-05-07 EP EP04075402A patent/EP1419783A3/fr not_active Withdrawn
- 1999-05-07 AU AU38899/99A patent/AU758825B2/en not_active Ceased
- 1999-05-07 EA EA200100029A patent/EA004538B1/ru not_active IP Right Cessation
- 1999-05-07 MX MXPA00012286A patent/MXPA00012286A/es unknown
- 1999-05-07 NZ NZ508823A patent/NZ508823A/en not_active IP Right Cessation
- 1999-05-07 NZ NZ527473A patent/NZ527473A/en not_active IP Right Cessation
- 1999-05-07 ES ES99921778T patent/ES2224659T3/es not_active Expired - Lifetime
- 1999-05-07 PL PL99345212A patent/PL195662B1/pl unknown
- 1999-05-07 HU HU0102193A patent/HUP0102193A2/hu unknown
- 1999-05-07 BR BR9911112-8A patent/BR9911112A/pt not_active IP Right Cessation
- 1999-07-05 UA UA2000127165A patent/UA69412C2/uk unknown
2000
- 2000-12-11 IL IL140223A patent/IL140223A/en not_active IP Right Cessation
- 2000-12-12 NO NO20006336A patent/NO20006336L/no not_active Application Discontinuation
- 2000-12-21 BG BG105079A patent/BG64975B1/bg unknown
2003
- 2003-07-03 AU AU2003212050A patent/AU2003212050B2/en not_active Ceased

Also Published As

Publication number	Publication date
OA11694A (en)	2005-01-12
JP2002517469A (ja)	2002-06-18
US7265087B1 (en)	2007-09-04
WO1999064061A1 (fr)	1999-12-16
NZ508823A (en)	2003-10-31
TR200100079T2 (tr)	2001-06-21
IL140223A (en)	2010-12-30
PL195662B1 (pl)	2007-10-31
CZ20004614A3 (en)	2001-06-13
CA2334872C (fr)	2014-08-19
ATE270897T1 (de)	2004-07-15
AU2003212050A1 (en)	2003-08-14
PL345212A1 (en)	2001-12-03
CZ294848B6 (cs)	2005-03-16
EA004538B1 (ru)	2004-06-24
CN1311687A (zh)	2001-09-05
EP1419783A2 (fr)	2004-05-19
IL140223A0 (en)	2002-02-10
CN1209166C (zh)	2005-07-06
HUP0102193A2 (hu)	2001-10-28
BG64975B1 (bg)	2006-11-30
EP1419783A3 (fr)	2005-01-12
SK19042000A3 (sk)	2001-11-06
DE69918691D1 (de)	2004-08-19
BG105079A (en)	2001-09-28
NO20006336L (no)	2001-02-12
PT1083924E (pt)	2004-10-29
MXPA00012286A (es)	2002-10-17
GEP20033015B (en)	2003-07-25
DE69918691T2 (de)	2005-07-21
AU758825B2 (en)	2003-04-03
UA69412C2 (uk)	2004-09-15
AP2001002027A0 (en)	2001-03-31
ID28617A (id)	2001-06-21
NO20006336D0 (no)	2000-12-12
ES2224659T3 (es)	2005-03-01
BR9911112A (pt)	2001-11-27
CA2334872A1 (fr)	1999-12-16
EP1083924A1 (fr)	2001-03-21
AU3889999A (en)	1999-12-30
AU2003212050B2 (en)	2006-02-16
NZ527473A (en)	2005-02-25
KR20010052800A (ko)	2001-06-25
EA200100029A1 (ru)	2001-10-22
EP1083924B1 (fr)	2004-07-14

Publication	Publication Date	Title
DK1083924T3 (da)	2004-11-22	Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance
GB2339963B (en)	2001-03-28	Producing thin film photovoltaic modules with high integrity interconnects and dual layer contacts
ITTO950741A0 (it)	1995-09-19	Cisterna stagna e termicamente isolante perfezionata integrata in una struttura portante.
AU4254485A (en)	1985-12-05	Electrochemcial cell with fluoride in electrolyte
GB9808944D0 (en)	1998-06-24	Electrochemical display and timing mechanism with migrating electrolyte
AU7882298A (en)	1998-10-08	Improvements in and relating to latches for gates
NO854424L (no)	1986-05-09	Elektrode for elektrokjemiske prosesser, fremgangsmaate for deres fremstilling og bruk i elektrolyseceller.
DK1060316T3 (da)	2003-09-15	Forbedringer ved eller i forbindelse med hængsler
DE3878374D1 (de)	1993-03-25	Oxidationsbestaendige molybdaeneinschmelzung und deren verwendung in lampen.
DE60033735D1 (de)	2007-04-19	Sammelschienenstruktur in einer elektrochemischen Zelle
DE69301172D1 (de)	1996-02-15	Neues Depolarisationsmittel enthaltender Elektrolyt sowie diesen Elektrolyt enthaltender elektrolytischer Kondensator
BR9507066A (pt)	1997-09-30	Uso de carboidrato complexo para diminuir hipoglicemia em pacientes com diabetes mellitus
IT1185825B (it)	1987-11-18	Fibra di poliacrinitrile avente elevata resistenza ed elevato modulo elastico
DE69738734D1 (de)	2008-07-10	Verbesserungen bei oder in Verbindung mit Servern
FI980507A0 (fi)	1998-03-05	Mer- och/eller extrakapacitetens realisering i basstationtransmission
ID21925A (id)	1999-08-12	Peningkatan pada atau yang berhubungan dengan kaca berlapis
NO20014011D0 (no)	2001-08-17	Glukosedehydrogenasefusjonsproteiner og deres anvendelse i ekspresjonssystemer
AU2370195A (en)	1995-11-29	Cell lines obtained by (in vivo) migration and by fusion with autoimmune cells
IT8682813A0 (it)	1986-07-03	Correttore elettronico dei difetti di curvatura sull'immagibe, per telescopi forniti di elementi cataottrici leggeri grande diametro, da usare anche in orbita.
IL145056A0 (en)	2002-06-30	Expression of human alpha-fetoprotein in mammalian cells
DK8193D0 (da)	1993-01-25	Haandtag i forbindelse med drejeligt laag
Rand	1993	Fifth Asian Battery Conference
MX9207192A (es)	1993-06-01	Catodo para usarse en celda electrolitica.
AU5683099A (en)	2000-03-14	Blockade of glucose toxicity to the beta cells in the islets of langerhans
Thompson	1994	Ecunomic aid